Freenome said the FDA approved its SimpleScreen CRC blood-based test for colorectal cancer, with Abbott set to exclusively commercialize it starting this fall. The assay is positioned as a complementary option to existing stool-based testing strategies, using cell-free DNA signals and is intended for adults 45 and older at average risk.